Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways
Sandra B. Haudek, … , Michael D. Schneider, Douglas L. Mann
Sandra B. Haudek, … , Michael D. Schneider, Douglas L. Mann
Published September 4, 2007
Citation Information: J Clin Invest. 2007;117(9):2692-2701. https://doi.org/10.1172/JCI29134.
View: Text | PDF
Research Article Cardiology

TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways

  • Text
  • PDF
Abstract

Transgenic mice with cardiac-restricted overexpression of secretable TNF (MHCsTNF) develop progressive LV wall thinning and dilation accompanied by an increase in cardiomyocyte apoptosis and a progressive loss of cytoprotective Bcl-2. To test whether cardiac-restricted overexpression of Bcl-2 would prevent adverse cardiac remodeling, we crossed MHCsTNF mice with transgenic mice harboring cardiac-restricted overexpression of Bcl-2. Sustained TNF signaling resulted in activation of the intrinsic cell death pathway, leading to increased cytosolic levels of cytochrome c, Smac/Diablo and Omi/HtrA2, and activation of caspases -3 and -9. Cardiac-restricted overexpression of Bcl-2 blunted activation of the intrinsic pathway and prevented LV wall thinning; however, Bcl-2 only partially attenuated cardiomyocyte apoptosis. Subsequent studies showed that c-FLIP was degraded, that caspase-8 was activated, and that Bid was cleaved to t-Bid, suggesting that the extrinsic pathway was activated concurrently in MHCsTNF hearts. As expected, cardiac Bcl-2 overexpression had no effect on extrinsic signaling. Thus, our results suggest that sustained inflammation leads to activation of multiple cell death pathways that contribute to progressive cardiomyocyte apoptosis; hence the extent of such programmed myocyte cell death is a critical determinant of adverse cardiac remodeling.

Authors

Sandra B. Haudek, George E. Taffet, Michael D. Schneider, Douglas L. Mann

×

Figure 8

Myocardial c-FLIPL and C-FLIPS levels.

Options: View larger image (or click on image) Download as PowerPoint
Myocardial c-FLIPL and C-FLIPS levels.
               
(A) Cytosolic pro...
(A) Cytosolic protein levels of c-FLIPL and c-FLIPS were determined in 12-week-old littermate control, MHCsTNF, MHCsTNF/Bcl-2, and Bcl-2 mouse hearts by Western blotting. Group data for the corresponding protein levels (normalized to GAPDH) are shown as the ratio of experimental (transgenic) to control (wild-type) mouse groups. (B) c-FLIPL mRNA levels were determined by RNase protection assay, and representative results as well as group data (normalized to L32) are shown. **P < 0.05 compared with LM.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts